Abdul Qazi, MD
Interventional Cardiology · Hartford, CTNPI 1699115691
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (45.9%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Penumbra, Inc. at 56.1% of the total. Among interventional cardiology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 274 payments — averaging $140.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$22K
- Abbott$5K
- Medtronic$5K
- Edwards Lifesciences$4K
- Inari Medical, Inc.$365
- Johnson & Johnson$346
- plus $2K from 21 others
What the payments were for
- Speaking & faculty fees$9,60025%
- Grants$4041%
- Travel & lodging$17,63946%
- Food & beverage$10,60528%
- Education$2101%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 43 | $21,589 |
| Abbott | 32 | $5,446 |
| Medtronic(2 entities) | 40 | $4,996 |
| Edwards Lifesciences | 83 | $3,981 |
| Inari Medical, Inc. | 5 | $365 |
| Johnson & Johnson | 19 | $346 |
| Boston Scientific | 3 | $270 |
| Angiodynamics, Inc. | 3 | $265 |
| Pfizer | 8 | $185 |
| E.r. Squibb & Sons, L.L.C. | 7 | $148 |
| Cardiovascular Systems Inc. | 1 | $141 |
| Boehringer Ingelheim | 4 | $95 |
| Abiomed | 2 | $85 |
| Novo Nordisk | 3 | $70 |
| Lexicon Pharmaceuticals, Inc. | 4 | $67 |
| AstraZeneca | 3 | $56 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $50 |
| Shockwave Medical, Inc | 1 | $46 |
| Merck | 2 | $45 |
| Philips North America LLC | 1 | $34 |
| Heartflow, Inc. | 1 | $32 |
| Amgen | 1 | $32 |
| Lantheus Medical Imaging, Inc. | 1 | $28 |
| Stryker | 1 | $26 |
| Novartis | 1 | $23 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$20,915
- OPTIS$2,614
- COREVALVE EVOLUT R$1,414
- CoreValve Evolut$1,211
- Omnilink Elite vascular stent system$1,156
- MitraClip$945
- Abre$443
- Admiral Xtreme$404
- FLOWTRIEVER CATHETER, S$300
- CT THROMBECTOMY SYSTEM KIT$300
- RUBY Coil$237
- Integrity$210
- SAPIEN 3 Ultra RESILIA$149
- Diamondback Peripheral$141
- Diamondback Coronary$141
- GENERAL VASCULAR ACCESS$130
- AngioVac$130
- AlphaVac$124
- GENERAL VASCULAR INTERVENTION$103
How this compares
$38,457 in reported general payments places this provider in the 90th percentile of 73 interventional cardiology providers in Connecticut.
See all interventional cardiology providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrilintaTicagrelor | 73 | $58,565 |
| EliquisApixaban | 52 | $42,250 |
| EntrestoSacubitril/Valsartan | 20 | $23,703 |
| XareltoRivaroxaban | 13 | $14,722 |
| Metoprolol Succinate | 69 | $961 |
| Atorvastatin Calcium | 109 | $826 |
| ClopidogrelClopidogrel Bisulfate | 66 | $629 |
| Amlodipine Besylate | 80 | $435 |
| Metoprolol Tartrate | 34 | $281 |
| Carvedilol | 31 | $251 |
| Rosuvastatin Calcium | 11 | $152 |
| Losartan Potassium | 19 | $147 |
| Furosemide | 20 | $109 |
| Lisinopril | 15 | $47 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBrilinta | $56 | $58,56573 claims |
| PfizerEliquis | $185 | $42,25052 claims |
| NovartisEntresto | $23 | $23,70320 claims |
| Johnson & JohnsonXarelto | $346 | $14,72213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 73 interventional cardiology providers in Connecticut.
Other interventional cardiology in Hartford
- Craig ThompsonHartford$222K
- Sarfaraz MemonHartford$30K
- Boskey PatelHartford$20K
- Joseph IngrassiaHartford$16K
- Talhat AzemiHartford$12K
- Bryan PiccirilloHartford$12K
- Immad SadiqHartford$9K
- Asad RizviHartford$5K
- Daniel FramHartford$3K
- Arslan MasoodHartford$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.